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To my family
Otorrhea and early tympanostomy tube
(TT) occlusion represent a major problem
in the outcome of patients after TT inser-
tion. Because albumin coating of implant
devices can prevent adhesion of platelets,
proteins, and bacteria, this study investi-
gated whether TTs coated with albumin are
more resistant to typical TT sequelae than
are uncoated tubes.
Three studies with albumin-coated TTs
and one study with titanium implants were
conducted: The binding of fibronectin, one
of the most adhesive proteins known, on
these TTs was tested first (I). Next, to learn
whether the albumin coating is durable on
the implant surface, an 8-month trial tested
the adhesion of fibronectin to the TT sur-
face after storage of the tubes for 1, 3, and 8
months in three environments (II). Adhe-
sion was then tested of the two most typical
bacteria causing TT otorrhea, Staphylococcus
aureus and Pseudomonas aeruginosa, to albu-
min-coated and -uncoated titanium implant
plates (III). After these in vitro experiments,
knowing that the albumin-coated surface
is repellent to both bacterial and protein
adhesion, the effectiveness of the method
was tested in a prospective clinical study
(IV). In this prospective randomized dou-
ble-blind follow-up, the 170 patients
enrolled suffered from otitis media with
effusion (OME) or recurrent acute otitis
media (RAOM). To discover the difference
in frequency of sequelae in albumin-coated
and uncoated tubes, one of each type 
(total : two) was inserted into each patient.
The results indicated that the albumin-
coated surface was resistant to protein adhe-
sion (I) and bacterial adherence (III), and
that the capacity to prevent adhesion of this
protein endured for the entire 8-month trial
(II). In the prospective trial (IV), incidence
of typical sequelae of tympanostomy, otor-
rhea and early tube occlusion, in the albu-
min-coated tubes were diminished. Early
tube occlusion was half as frequent in the
ears with albumin-coated tubes (IV). Espe-
cially in patients with perioperative bleeding
was this difference marked.
An implant coated with albumin is thus
resistant to protein and bacterial adhesion
in vitro, and the coating is durable. Albumin
coating of TTs can provide in vivo an effec-
tive method to limit the number of TT
sequelae.
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ABSTRACT
Ilmastointiputken asettaminen tärykalvoon
on yksi yleisimmistä lapsille tehtävistä toi-
menpiteistä. Putken kautta tuleva märkä-
vuoto ja ilmastointiputken ennenaikainen
tukkeutuminen ovat merkittävimmät kysei-
sen hoidon tehoa uhkaavista ongelmista.
Koska muissa elimistöön asetettavissa
materiaaleissa on voitu todeta, että albu-
miinipinnoitus vähentää bakteerien ja veri-
hiutaleiden tarttumista materiaalin pintaan,
halusimme selvittää vähentääkö albumiini-
pinnoitus edellä mainittuja ongelmia täry-
kalvon ilmastointiputkissa. 
Neljässä erillisessä tutkimusessa selvi-
tettiin humaani seerumin albumiini (HSA)
-pinnoituksen vaikutusta tärykalvon ilmas-
tointiputkien ja titaanilevyjen ominaisuuk-
siin: ensimmäisessä tutkimuksessa selvi-
tettiin yleisimmän elimistön liimaproteii-
nin, fibronektiinin, tarttuvuutta albumiini-
pinnoitettuun ja pinnoittamattomaan
ilmastointiputkeen (I). Toisessa tutkimuk-
sessa selvitettiin albumiinipinnoituksen
pysyvyyttä. Pinnoitettuja ja pinnoittamatto-
mia ilmastointiputkia säilytettiin lämmön ja
ilmankosteuden suhteen erilaisissa ympä-
ristöissä 1, 3 ja 8 kuukauden ajan, jonka jäl-
keen testattiin fibronektiinin tarttuvuus put-
kiin (II). Kolmannessa tutkimuksessa sel-
vitettiin tyypillisimpien putkivuotoa aiheut-
tavien bakteerien, Staphylococcus aureuksen
ja Pseudomonas aeruginosan, tarttuvuus
albumiinipinnoitettuun ja pinnoittamatto-
maan titaanilevyyn (III). Koska edellä mai-
nituissa tutkimuksissa selvisi, että albu-
miinipinnoitettu materiaali hylkii sekä bak-
teereja että proteiineja, teimme prospektii-
visen, satunnaistetun potilastutkimuksen
albumiinipinnoituksen kliinisen tehon sel-
vittämiseksi (IV). Kyseessä oli kaksoissok-
koutettu seurantatutkimus, johon otettiin
170 potilasta. Potilaat tulivat tärykalvojen
putkitukseen joko liimakorvataudin tai tois-
tuvien akuuttien välikorvatulehdusten vuok-
si. Jokainen potilas sai toiseen korvaan pin-
noitetun ja toiseen pinnoittamattoman
titaaniputken.
Tulokset osoittavat, että albumiinipin-
noitus vähentää liimaproteiinin (I) ja bak-
teerien tarttuvuutta (III), ja että pinnoituk-
sen aikaansaama liimaproteiinin tarttu-
vuutta hylkivä ominaisuus säilyy pinnoite-
tussa putkessa 8 kuukauden varastoinnin
aikana (II). Prospektiivisessa tutkimukses-
sa ilmeni, että tyypillisimpien putkituksen
tehoa uhkaavien ongelmien määrä oli pie-
nempi albumiinipinnoitetuissa putkissa
(IV). Verrattuna pinnoittamattomaan titaa-
niputkeen, kolmen ensimmäisen seuran-
takuukauden aikana putkitukoksia todet-
tiin 50 % vähemmän albumiinipinnoite-
tuissa putkissa. Erityisen merkittävä ero oli
potilailla, joiden korvissa ilmeni verenvuo-
toa putkituksen yhteydessä.  
Ilmastointiputken pinnoitus albumii-
nilla vähentää proteiinien ja bakteerien tart-
tuvuutta in vitro ja pinnoituksen tuottama
tarttuvuutta vähentävä ominaisuus on pit-
käkestoinen. Tärykalvon ilmastointiputkien
pinnoittaminen albumiinilla tarjoaa käy-
tännössä tehokkaan tavan rajoittaa putkissa
ilmenevien ongelmien määrää. 
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Otitis media is one of the most usual child-
hood diseases. In children suffering either
from recurrent acute otitis media (RAOM)
or otitis media with effusion (OME) unre-
sponsive to nonsurgical treatment, tympa-
nostomy (myringotomy with TT insertion)
has become the treatment of choice (Blue-
stone and Klein 1995). In the operation, a
tube usually of silicone or titanium is
implanted into an incision through the
tympanic membrane. Tympanostomy is
one of the most common operations on
children in the industrialized countries. In
the USA, where 2 million tympanostomy
tubes (TT) are manufactured annually
(Isaacson and Rosenfeld 1996), it is the
most common pediatric procedure under
general anesthesia (Derkay 1993). A TT is
expected to bypass the malfunctioning
eustachian tube and to secure middle ear
ventilation so that the middle ear mucosa
can heal by itself. The most typical seque-
lae with TTs are otorrhea through the tube
and tube occlusion before its expected
extrusion time (Kay et al. 2001). These
problems are associated with contamina-
tion of the tube by exudates and bacteria
(Karlan et al. 1981).
Many different methods to reduce TT
sequelae have been tested: both systemic
and local peri- and post-operative medica-
tions and ear canal treatments of different
magnitude. Hundreds of tube models and
materials exist, as well as tube coatings.
Experiments show that tube model and
material each play a role in the incidence of
tube sequelae. For instance, silver oxide
(AgO) coating on TTs diminishes the inci-
dence of otorrhea (Chole and Hubbel 1995).
Tube ionization has also shown potential in
preventing tube contamination (Biedling-
maier et al. 1998).
Human serum albumin (HSA) has
served as a plasma expander since World
War II. The antiadherent characteristics of
an HSA coating were already reported by
Packham and colleagues in 1967. Since the
1970s, the HSA coating has served in extra-
corporeal hemoperfusion systems to pre-
vent platelet adhesion and the subsequent
blood clot formation on artificial surfaces of
hemoperfusion devices. The HSA coating is
also helpful in porous arterial graft pros-
theses to prevent bleeding through the
prostheses during surgery. In the last
decade, interest in the possibility to use the
antiadherent characteristics of the HSA
coating against peri- and postoperative bac-
terial contamination of implants has grown.
Several in vitro and in vivo tests with HSA-
coated implants (Lubin et al. 1986, Kottke-
Marchant et al. 1989, Zdanowski et al.
1993, McDowell et al. 1995, An et al. 1996)
have shown in all cases that the HSA coat-
ing provides an effective weapon against
unwanted adhesion on and contamination
of implants.
The research project presented here was
conducted to study the effect of albumin
coating on the properties of TTs both in
laboratory surroundings and in real life.
Until now, few if any prospective random-
ized clinical trials have examined HSA-coat-
ed implanted devices. 
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2.1 OTITIS MEDIA 
2.1.1 DEFINITION 
Acute Otitis Media (AOM) is a clinically
identifiable infection of the middle ear with
acute onset of signs and symptoms and
short duration (Klein et al. 1989). The
appearance of the tympanic membrane is
changed in AOM, and fluid is present in
the middle ear (Puhakka et al. 1999). The
nonspecific signs associated with AOM are
fever, irritability, headache, apathy, anorex-
ia, vomiting, and diarrhea. The most typical
specific signs and symptoms are otalgia,
otorrhea, hearing loss, and rarely vertigo,
nystagmus, tinnitus, swelling of the ear,
facial paralysis, and purulent conjunctivitis.
AOM can occur with all or without any of
these symptoms, and none of them, except
purulent otorrhea, is reliable for diagnosis
(Bluestone and Klein 1995).
Otitis media with effusion (OME) is a
noninfectious condition without acute signs
and symptoms with middle ear effusion
(MEE) behind an intact tympanic mem-
brane (Klein et al. 1989). Usually, after
AOM, if MEE poorly resolves, it results in
OME (Klein et al. 1989).
2.1.2 EPIDEMIOLOGY
Among pediatric patients, AOM is an
extremely common disease. During the first
2 years of life, 70% to 91% of children expe-
rience at least one episode of AOM (Teele et
al. 1989, Paradise et al. 1997), and some
become ”otitis-prone,” with six or more
episodes of AOM before the age of 6
(Howie et al. 1975, Faden et al. 1998). AOM
accounts for 20 to 40% of all office visits
for children under 6 in the USA (Teele et
al. 1983).  Furthermore, it is the most com-
mon cause of hearing loss during child-
hood (Teele et al. 1990). The incidence of
otitis media is highest in spring and
autumn, increasing close to the end of the
first year of life and decreasing during the
second year (Alho et al. 1991). Despite all
efforts, the incidence of AOM and subse-
quent OME is rising. (Lanphear et al. 1997,
Joki-Erkkilä et al. 1998). In Finland, cases
of pediatric AOM diagnosed annually
amount to half a million (Niemelä et al.
1999). 
Incidence of OME is also dependent on
age and time of year, being the highest in
winter moths and during the second year of
life (Bluestone and Klein 1995). In healthy
children from 2 to 4, incidence of OME
varies between 14.6% and 18.1% (Tos and
Poulsen 1979, Tos et al. 1982).  Sponta-
neous recovery from OME is very common,
especially in the summer months: Between
May and August, resolution of MEE can
occur in up to 66% of cases (Tos and
Poulsen 1979).
Because AOM is such a common dis-
ease, it causes marked financial losses both
to the families and to the community. In
the end of the 1990’s, total annual cost of
treating otitis media in Finland was an esti-
mated € 115 million, the average cost of
each attack of AOM was € 189, and the
average annual cost arising from otitis
media per child under age 2, with all costs
such as visits to physicians, medication,
parents’ absence from work, and cost of
surgery included, were € 863 (Niemelä et al.
15
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1999).  In the United States in 1997 the
average cost of a simple episode of AOM
was € 203 and of a complex case, with sev-
eral visits and possible hospitalization, was
€ 607 (Capra et al. 2000). 
2.1.3   ETIOLOGY AND PATHOGENESIS
The pathogenesis of otitis media is a com-
plex combination of factors such as viral or
bacterial infection, eustachian tube dys-
function, allergy, and the poor status of the
immunosystem. Furthermore, environ-
mental and social status contributes to its
incidence (Paradise et al. 1997). The major
risk factors associated with AOM are male
sex, sibling history of AOM, early occur-
rence of first attack of AOM, and lack of
breast feeding (Teele et al. 1989). In chil-
dren, immature function of the eustachi-
an tube (Bluestone et al. 1972) with ascend-
ing viral or bacterial pathogens of the
nasopharynx (Rosenfeld 1996) seems to be
the main factor promoting otitis media. The
most usual bacteria involved are Streptococ-
cus pneumoniae, Haemophilus influenzae,
and Branhamella catarrhalis (Bluestone et
al. 1992). Evidence of viral RNA has been
detected in as high as 48% of AOM
episodes (Pitkäranta et al. 1998).
The pathogenesis of OME is complex,
as well. OME is diagnosed when MEE
occurs in an asymptomatic ear. OME usu-
ally occurs after AOM with poor resolution
of the MEE but can also arise sponta-
neously without pre-existing AOM symp-
toms (Rosenfeld 1996). Of the bacteria
causing AOM, H. influenzae is isolated
most frequently from patients with OME
(Bluestone et al. 1992). Drainage from the
MEE is blocked by the inflammatory
swelling of the mucosa and impaired ciliary
function in the middle ear which are medi-
ated by cytokines and inflammatory medi-
ators (Ganbo et al. 1995). In OME, the
number of middle ear mucosal secretory
cells increases, leading to formation of a
mucin-rich effusion in the middle ear (Tos
1980, Carrie et al. 1992).  Resolution of
MEE is impaired more frequently in chil-
dren because of their immature eustachian
tube anatomy (Bluestone and Klein 1995).
Recently, during AOM and OME, biofilm
has been found covering the middle ear
mucosal surface (Post 2001, Fergie et al.
2004). Evidence supporting the role of
biofilm formation in the pathogenesis of
AOM and OME may explain the fact that in
OME, bacterial cultures often show no
pathogens (Qvarnberg et al. 1990). 
2.1.4 CLINICAL COURSE
Often AOM heals even without any special
treatment in a few weeks (Burke et al.
1991), but prolonged and recurrent cases
of otitis media are not rare (Pukander et al.
1982, Rosenfeld et al. 1994, Jero et al.
1997). During AOM, fluid is produced in
the middle ear. Usually this fluid gradually
disappears during the one to four-week
healing process (Teele et al. 1980), but
sometimes the inflammation continues
without symptoms because of increasing
obstruction of the eustachian tube, leading
to failed middle ear clearance and reten-
tion of fluid in the middle ear, OME
(Shurin et al. 1979).
In OME, the middle ear fluid can be
either serous, mucoid or purulent (Tos
1980). Spontaneous resolution of the MEE
is also usual in OME. Incidence of MEE one
month after the first diagnosis of OME is
33%, after 2 months 20%, and after 2 years
2% (Thomsen and Tos 1981, Casselbrant et
al. 1985). On the other hand, in patients
with bilateral OME continuing for at least 3
months, likelihood of spontaneous resolu-
tion of the MEE is worse. The incidence of
MEE in this group after 6 months has been
80%, after one year 78%, and after 3 years
51% (Maw and Bawden 1994 a).
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2.1.5 COMPLICATIONS
The most usual complication after AOM
and OME is hearing loss, which occurs to
some extent in all ears with effusion (Teele
et al. 1990). Fluid production in the middle
ear gradually impairs the movement of the
tympanic membrane, which causes con-
ductive hearing loss (Bluestone and Klein
1995). Such hearing loss caused by untreat-
ed OME or recurrent AOM can lead to
retardation of language skills and attention
(Bluestone et al. 1983). In a group of chil-
dren with cleft palate and OME treated with
early TT placement, hearing acuity and
consonant articulation was significantly less
impaired than in children who had under-
gone myringotomy later (Hubbard et al.
1985). Several episodes of AOM in early
life, even if effectively treated, can harm
reading comprehension as late as at 9 years
of age (Luotonen et al. 1996).
The more severe complications of AOM
with inflammation spread intratemporally
in areas such as mastoid cells, the petrous
portion of the temporal bone, or inner ear,
causing mastoiditis, facial paralysis,
labyrinthitis, or sensorineural hearing loss,
or intracranially, causing meningitis, brain
abscess, or lateral sinus thrombosis, are
rare (Bluestone and Klein 1995, Goldstein
et al. 1998, Bluestone 2000). At present,
less than 0.5% of the cases of AOM are
associated with serious complications,
compared with an incidence before the
antibiotic era of over 40% (van Buchem et
al. 1985).
2.1.6 DIAGNOSIS AND TREATMENT
Diagnosis of AOM and OME is based on
medical history, the typical signs and symp-
toms listed above, and physical examina-
tion. The examination includes a general
examination and pneumatic otoscopy
(Puhakka et al. 1999). Because of difficul-
ties often found in identifying an ear with
effusion, either tympanometry or otomi-
croscopy is often recommended to confirm
the diagnosis, especially when OME is sus-
pected (Cantekin et al. 1980, Palmu et al.
1999).
Although spontaneous resolution of
AOM is usual, antibiotic treatment is rec-
ommended (Rosenfeld 1996, Puhakka et
al. 1999). Because of the high incidence of
AOM, concern is growing as to overuse of
antibiotics in its treatment. In the USA,
over one-quarter of all oral antimicrobial
agents are prescribed for AOM (Bluestone
1998). It has been estimated that for every
seven children with AOM treated with
antibiotics, only one really benefits (Rosen-
feld et al. 1994). Based on the current con-
sensus in treating AOM in Finland, antibi-
otic treatment with efficacy against the
three major bacterial pathogens in AOM is
recommended, but in selected cases watch-
ful waiting with pneumatic otoscopy for 1 to
2 days after the first diagnosis of AOM is
acceptable (Puhakka et al. 1999). Symp-
toms of AOM can also be relieved with
analgesic medication. For recurrent attacks
of AOM—three or more episodes during
the preceding 6 months—TT insertion can
be helpful (Bluestone and Klein 1995). 
The effect of artificial middle ear
drainage and aeration with a tympanic
membrane incision in curing AOM was
first described by the English surgeon Sir
Astley Cooper (Alberti 1974), who planted
the seed for the growth of tradition of
myringotomy 200 years ago. Despite the
traditional rule of surgery, “ubi pus ibi
evaqua,“ myringotomy in treating AOM vir-
tually ceased during the era of antibiotic
treatment begun in the 1940s. In recent
decades, the procedure has been limited
only to those children with severe otalgia
and suppurative complications such as
mastoiditis (Bluestone and Klein 1995). In
part, this is due to the dramatic increase in
tympanostomy procedures during the last 3
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decades (Black 1984), to the fact that inci-
dence of the fearsome complications of
AOM has been low (van Buchem et al.
1985), and to the fact that the relief of hear-
ing loss and pain in AOM achieved with
myringotomy is brief because the middle
ear can rapidly again fill with fluid after the
procedure (Berger 1989). 
OME found in a symptomless patient is
most likely due to an extension of AOM
and usually resolves spontaneously (Blue-
stone and Klein 1995). Systemic steroid
treatment has some limited effect in facili-
tating the spontaneous resolution of the
MEE (Rosenfeld et al. 1991). In cases with
MEE persisting over 3 months or unre-
sponsive to medical treatment or in cases
with shorter-length but severe conductive
hearing loss, treatment with TTs is indicat-
ed (Bluestone and Klein 1995).
Adenoidectomy has been widely used
as a treatment for RAOM or OME. Recent
investigations have, however, shown that
adenoidectomy, as the primary method of
prophylaxis, has little effect on further
episodes of AOM in children under 2, the
age-group in which the incidence of AOM
is highest (Koivunen et al. 2004). 
2.2 TYMPANOSTOMY
2.2.1 TYMPANOSTOMY OPERATION
Placement of a tube in the myringotomy
incision was suggested first by Adam Poliz-
er in the 1860’s (Alberti 1974).  Not until
Armstrong reported his favorable results
in treating five patients with this method 50
years ago, in June 1954, did the method
become popular. After the late 70´s TT
placement has become the most common
surgical procedure among children in many
western countries such as the USA, the
Netherlands, and England (Black 1984). In
Finland, tympanostomy is performed on
10% of all children before the age of 5 years
(Niemelä et al. 1999) and in the Nether-
lands, 2% of all children younger than 12
years receive TTs yearly (Schilder et al.
2004). In the USA, the number of TTs
manufactured yearly is about 2 million
(Isaacson and Rosenfeld 1996), and they
are inserted annually into more than a mil-
lion children (Mandel et al. 1984), which
makes this the most common pediatric pro-
cedure performed under general anesthesia
there (Derkay 1993). Because the incidence
of AOM and OME is highest in children
under 2, the majority of TTs are inserted in
this age-group (Myer and France 1997). The
surgical treatment of OME with TTs has
been found cost-effective when recurrent
OME fails to respond to medical therapy
(Gates 1996).
In the operation, an incision is made
into the anterior part of the tympanic mem-
brane, thus protecting the ossicular chain
located behind the posterosuperior part and
the round window membrane located
behind the posteroinferior part of the tym-
panic membrane. Fluid, if present, is rou-
tinely aspirated from the middle ear before
the tube, usually with wide flanges at both
ends, is inserted in the incision made in
the tympanic membrane. The open tube
allows the fluid to drain out and the venti-
lation of the middle ear, and restores hear-
ing. The effect of TT treatment for bilateral
OME lasting 3 months and unresponsive to
nonsurgical treatment has been convinc-
ingly shown in several prospective studies
(Gates et al. 1987, Mandel et al. 1989 and
1992). Furthermore, in treating AOM, the
efficacy of TT has been evident among
patients suffering from frequently recur-
ring attacks of AOM three or more times
during the preceding 6 months, along with
failure in chemoprophylaxis (Gebhart 1981,
Gonzalez et al. 1986, Casselbrant et al.
1992, Giebink 1994).
Normally the TT stays patent in the
tympanic membrane from 6 to 18 months,
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depending on the model and material of
the tube (van Baarle and Wentges 1975,
Handler et al. 1986 and 1988). The most
common collar-button style tube, with wide
flanges set at right angles to the lumen of
the tube, stays in place about twice as long
as the Shepard style tube with its shallow
curve at the neck of the tube and minimal
flanges (Moore 1990). Furthermore, short-
er-range middle ear ventilation without
tubes is available with laser-assisted
myringotomy, although more relapses
occur with this method (Silverstein et al.
1996). While the artificial middle ear ven-
tilation is functioning, water-entry to the
middle ear through the tube may lead to
complications. Although the routine use of
earplugs while bathing or swimming is not
indicated unless the child has had frequent
bouts of otorrhea, submersion in soapy
water or deep submersion in any water
increases risk for middle ear contamina-
tion (Pashley and Scholl 1984, Hebert et
al. 1998). 
The TTs migrate posteriorly around the
umbo with the migrating epithelial layer of
the tympanic membrane and finally extrude
from the tympanic membrane, pushed out
by the squamous debris which over time
accumulates under the outer flange of the
tube (van Baarle and Wentges 1975, Isaac-
son and Rosenfeld 1996). Surgical removal
of the tube is required in cases where the
tube, usually for an unknown reason, does
not extrude spontaneously. Watchful wait-
ing for at least 2 years after the tympanos-
tomy procedure is recommended before
any such procedures are done, if the tube is
functioning normally, due to the risk for
persistent perforation after tube removal
(Cunningham et al. 1993, El-Bitar et al.
2002). 
A child with TTs needs careful follow-
up at 4- to 6-month intervals and at least
one follow-up visit 6 to 12 months after
tube extrusion for early detection of any
possible TT sequelae (Rosenfeld and Blue-
stone 1999, Kokko 1974). Approximately
26% of tympanostomized patients will
require re-tympanostomy after tube extru-
sion (Casselbrant et al. 1992). One expla-
nation is continuing eustachian tube dys-
function. The effect of adjuvant adenoidec-
tomy, tonsillectomy, or both on outcome
of tympanostomized children is currently
under active debate (Paradise et al. 1990,
Coyte et al. 2001, Mattila et al. 2003). Dur-
ing the present era of antibiotic-resistant
bacteria, the role of surgical procedures in
treating such overwhelmingly common dis-
eases as recurrent AOM and OME has
become even more important (Bluestone
1998). 
2.2.2 SEQUELAE OF TYMPANOSTOMY 
Although TT insertion is a widely accepted,
effective treatment for curing the conduc-
tive hearing loss in OME (Shah 1971), and it
has been shown to improve the patient’s
quality of life (Facione 1991, Urben and
Nichols 1996, Hellier et al. 1997), some
sequelae can arise. The main problems
interfering with TT function are early occlu-
sion of the tube and inflammation of the
middle ear with a purulent discharge, otor-
rhea (Kay et al. 2001).  The tube becomes
occluded in as many as 36% of the cases
(Reid et al. 1988, Weigel et al. 1989). Usu-
ally the plug occluding the tube consists of
dried mucoid effusion (Westine et al. 2002
a). Tested perioperative methods to reduce
the incidence of tube occlusion, include
coating the tube or tympanic membrane
with vasoconstrictor solution (Altman et al.
1988, Jamal 1995) or Polysporin oph-
thalmic ointment (Cunningham and
Harley 1992), or using prophylactic antibi-
otic/steroid ear-drops (Salam and Cable
1993). When a TT is occluded, one can try
to solve the occlusion with ear drops (Bren-
man et al. 1986, Spraggs et al. 1995, West-
ine et al. 2002 b), or clear the blocked tube
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mechanically with suction and irrigation.
Clearance of the occluding plug may
depend on tube surface properties (Tsao et
al. 2003). In practice, methods to open an
occluded TT are difficult and painful to
carry out and usually not successful without
general anesthesia and tube removal
(Rosenfeld and Bluestone 1999). Almost
one-third of tube occlusions lead to tube
replacement (Per-Lee 1981). 
In 17% of the intubated ears, the treat-
ment is associated with otorrhea (Kay et al.
2001) which in OME is the most common
complication of tympanostomy (Gates et
al. 1986) and is the major problem threat-
ening the child’s quality of life after bilateral
tube placement (Debruyne et al. 1988,
Rosenfeld et al. 2000). Drainage through
the tube within the first few weeks after
tympanostomy is called early postoperative
otorrhea (Rosenfeld and Bluestone 1999).
Several perioperative methods such as pro-
phylactic antibiotic drops after TT place-
ment (Scott and Strunk 1992, Epstein et
al. 1992, Salam and Cable 1993, Hester et
al. 1995), preoperative external ear canal
disinfection (Baldwin and Aland 1990,
Giebink et al. 1992), and post-tympanosto-
my trimethoprim-sulfamethoxatzole and
prednisone treatment (Daly et al. 1995) are
aimed at preventing early postoperative
otorrhea in intubated ears, though degree of
surgical asepsis during tube placement has
no effect on risk for early postoperative otor-
rhea (Odutoye et al. 2003). Because one
study reported 17 children to be treated with
prophylactic ear-drops to prevent only one
case of postoperative otorrhea (Rosenfeld
and Bluestone 1999) and because of the
potential ototoxicity of some ear-drops
(Welling et al. 1994), their routine use is
not recommended (Garcia et al. 1994). The
bacteria found in a tube that is draining
are basically the same pathogens that cause
the AOM (Mandel et al. 1994).  In children
older than 3, however, bacteria considered
to be the normal flora of the external ear
canal occur more often than among the
younger patients: Incidence of Staphylococ-
cus aureus in the ear discharge can be 39%
and of Pseudomonas aeruginosa 24%
(Schneider 1989). One or both of these bac-
teria may occur in 44% of otorrhea
episodes in a tympanostomized ear (Man-
del et al. 1994). In chronic and recurrent
tube infections, as well, Staphylococcus
aureus and Pseudomonas aeruginosa occur
frequently (Brook et al. 1998). 
Early postoperative otorrhea and recur-
rent otorrhea—with three or more acute
episodes—occur more often in ears with
MEE present in tympanostomy (Valtonen et
al. 1997 and 1999). Chronic otorrhea is
associated more with long-term tubes
(Slack et al. 1987). Incidence of chronic
otorrhea lasting longer than 3 weeks in the
tympanostomized ear is 4% to 6% (Rosen-
feld and Bluestone 1999). The manage-
ment of acute, short-term otorrhea is usu-
ally simple, and the otorrhea sometimes
resolves even without treatment (Herzon
1980). The draining ear is usually cured
with saline rinsing and with both per oral
and local antibiotic treatment based on bac-
terial culture (Supance and Bluestone
1983). Studies supporting the effect of per
oral prednisolone as an adjuvant therapy
in AOM with discharge through the TT also
exist (Ruohola et al. 1999). Chronic otor-
rhea through the tube is often considered a
consequence of implant contamination,
and this is best cured by tube removal (Lux-
ford and Sheehy 1982, Bingham et al.
1989). 
A tympanic membrane irritated by the
tube may produce granulation tissue, the
most common cause of bloody otorrhea
(Rosenfeld and Bluestone 1999), and which
occurs in 6% of the ears with titanium
tubes (Handler et al. 1988, Cunningham
et al. 1993). Atrophy or a sclerotic plaque on
the tympanic membrane after tube extru-
sion are abundant, seen as often as in one-
quarter to one-third of all ears treated with
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TTs, but these are generally cosmetic prob-
lems that rarely cause any morbidity or
necessitate procedures (Goldstein et al.
1996, Kay et al. 2001). A chronic perfora-
tion of the tympanic membrane occurs in
2.2% of ears treated with conventional
short-term tubes; perforations occur more
often (12%) in ears treated with the long-
term tubes (Weigel et al. 1989, Matt et al.
1991, Kay et al. 2001). The most severe
complication of TT treatment, cholestea-
toma, occur in 0.7% of the tympanos-
tomized ears (Kay et al. 2001). TT place-
ment itself seems to cause no conductive or
sensorineural hearing loss (Emery and
Weber 1998). Although many of the TT
sequelae such as acute otitis media, otor-
rhea, tympanosclerosis, focal atrophy, and
even cholesteatoma can actually occur in
an unoperated ear of an otitis-prone child
and thus can rarely be attributed directly
to tube treatment, these tend to be more
frequent in a tympanostomized ear (Maw
and Bawden 1994 b, Kay et al. 2001, Daly et
al. 2003). 
2.3 MEDICAL BIOMATERIALS
2.3.1 DEFINITION
Medical biomaterials are the metal, ceram-
ic, and polymer materials or their compos-
ites used to build medical devices; a medical
implant is any object made of one or more
biomaterials that replaces a structure or
function of the body (Costerton et al. 1987,
DeMane 1995).
The properties of an ideal implant
material are, according to DeMane (1995),
that it is: noncarcinogenic, non-allergenic,
sterilizable, capable of fabrication in the
forms desired, capable of forming a living
bond to tissue, and of acting as a drug car-
rier or delivery depot, and capable of con-
trolled release of biologic proteins such as
bone morphogenic proteins. Unless the
material is biodegradable, it should be clin-
ically inert, structurally stable, not physi-
cally modifiable by tissue fluids, and not
illiciting any inflammatory or foreign body
response.
Today, biomaterial solutions are so
usual that in our technologically advanced
society almost every human being is host to
some biomaterial. Among the most com-
mon medical implants, next to dental fill-
ings, are TTs. Biomaterial surfaces may be
hydrophobic, like Teflon, plastic, latex, or
silicone, or hydrophilic, like glass or metals.
These materials are also characterized by
their surface texture, roughness or smooth-
ness, and antimicrobial properties. The sur-
face properties that most invite bacterial
adherence and biofilm formation are
roughness and hydrophobicity. (Donlan
2001).  
2.3.2 TYMPANOSTOMY TUBES 
TTs are constructed of polymers such as
silicone, polyethylene, or Teflon, metals
such as stainless steel, titanium, or gold,
and ceramics such as hydroxylapatite
(Heumann et al. 1982, Tami et al. 1987,
Shone and Griffith 1990). Hundreds of dif-
ferent tube models exist. Their design
varies from short- to long-shafted, with vari-
able sizes and forms for flanges and tube
lumens (Tavin et al. 1988, Lindstrom et al.
2004). Functionally, TTs are categorized
as short- or long-term tubes by the length of
time they are predicted to ventilate the mid-
dle ear. Short-term tubes stay open from
approximately 8 to 18 months, and long-
term tubes more than 15 months (Rosen-
feld and Bluestone 1999). The short-term
tube is suitable for most patients, with its
ventilation time sufficiently long to secure
the healing process of the middle ear with
an acceptable risk for sequelae. The long-
term tube is reserved for the rare cases
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needing a long middle ear ventilation peri-
od, despite a risk for persistent perforation
of the tympanic membrane and a high fre-
quency of otorrhea (Per-Lee 1981, Weigel et
al. 1989, Goode 1996,). Long-term T-tubes
are indicated, for example, for patients with
cleft palate or other craniofacial anomalies
leading to a need for lengthy middle ear
aeration (Wielinga and Smyth 1990). 
Because TT extrusion occurs as keratin
from the tympanic membrane accumulates
between the tympanic membrane surface
and the outer flange of the tube, finally
pushing the inner flange out through the
tympanic membrane, the main factors lead-
ing to late extrusion time are long inter-
flange distance, a large inner flange, and an
absent or small outer flange (Gordts et al.
1993, Isaacson and Rosenfeld 1996). A ker-
atin ring around the collar of an extruded TT
is often present (Reid et al. 1988). TT occlu-
sion occurs more often if the tube is long-
shafted or if the tube lumen diameter is
very small, but on the other hand, a larger
tube lumen will lead to more tympanic
membrane perforations after tube extrusion
(Bluestone and Klein 1995, Morris 1999). 
The role of the TT is to bypass a poorly
functioning eustachian tube, improve hear-
ing, and reduce symptoms caused by AOM
such as otalgia. To succeed, the TT lumen
must remain patent. The tube itself may
become colonized with pathogenic bacte-
ria, resulting in persistent infections, and
the tube material may play an important
role in development of otorrhea and tube
occlusion (Biedlingmaier et al. 1998). The
chemical composition and physical charac-
teristics of the surface of an implantable
device such as charge, hydrophobicity and
roughness are the main factors influenc-
ing bacterial adherence and the adhesion of
proteins as well as other molecules (An and
Friedman 1998). Teflon has low adhesive
properties, and Teflon tubes are smoother
than silicone tubes in scanning electron
microscopy (SEM) pictures; such smooth-
ness reduces bacterial adhesion capacity
(Karlan et al. 1980 and 1981, Quirynen et al.
1993). Less otorrhea occurs with Teflon
than with silicone tubes (Karlan et al. 1980).
Whether this is due to the chemical prop-
erties of Teflon or to the smoothness of the
tube surface is, however, unknown. 
Tube impregnation with a bactericidal
component such as silver oxide can reduce
the incidence of otorrhea in a tympanos-
tomized ear (Chole and Hubbell 1995,
Gourin and Hubbell 1999). Biomaterial
surface properties can also be changed with
ion implantation that alters the hydropho-
bicity of a surface and makes it more resist-
ant to adhesion (Sioshansi 1994).  Such
ionized silicone TTs show at least a short-
range resistance to bacterial biofilm forma-
tion in guinea pigs compared to that of con-
ventional tubes (Saidi et al. 1999). The
smoothness or roughness of the material
may also contribute to resistance against
bacterial colonization and biofilm forma-
tion. Recurrences of otorrhea in an ear with
a TT are often connected with typical risk
factors for RAOM, but as shown by Chole
and Hubbell (1995) the tube material can
also contribute to otorrhea. 
2.3.3 UNDESIRABLE ADHESION 
WITH BIOMATERIALS
Bacterial adhesion 
During recent decades, the number of
implantable devices has grown (DeMane
1995). The obvious problem with these
devices, implant-related infections, has
awakened interest in the mechanisms by
which the bacterial colonization and sub-
sequent infection develop. As bacteria pre-
fer to grow on a surface rather than sus-
pended in the surrounding medium, bac-
terial adhesion to the surface and coloniza-
tion of biomaterial are, in general, the initial
steps in development of biofilm formation
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and infections on biomaterials (Hogt et al.
1985, Wadstrom 1989). 
Adhesion of bacteria to the substratum
is divided into two phases. In the first
phase, long-range physicochemical inter-
actions such as gravitational forces or forces
of surface electrostatic charge, and short-
range interactions such as chemical bonds,
ionic and dipole interactions, and
hydrophobic interactions transport the bac-
teria close to the surface and facilitate their
initial attachment (Fletcher and Loeb 1979,
Krekeler et al. 1989, Mafu et al. 1991). In
the second phase, stronger adhesion of bac-
teria to the surface is achieved by the
adhesins in the bacterial capsules: fimbriae
and slime (An and Friedman 1998). Slime-
producing bacterial strains are more adher-
ent and pathogenic than others; they can
produce colonies of bacterial biofilm that
are strongly anchored to the surface of an
implanted device and can resist host
defense mechanisms and treatments
because of this protective slime cover
(Christensen et al. 1982). Moreover, cer-
tain bacterial surface components and sub-
strata exhibit specific adherence mecha-
nisms. Such a specific adhesion may also
be important in the pathogenesis of pros-
thetic infections (Timmerman et al. 1991).
Bacterial adhesion is a complex process
influenced by a material’s surface proper-
ties, by factors in the surrounding medium
and by environmental factors such as tem-
perature, bacterial concentration, exposure
time, and the presence of antibiotics
(Ørstavik 1977, Gristina 1987), as well as by
characteristics of the bacterial species and
strains. Furthermore, a totally implanted
device is rapidly coated with surrounding
proteins and immunocomplexes that can
mask the properties of the underlying sur-
face itself and promote bacterial adhesion
(Eberhart et al. 1987, An and Friedman
1998).
Differences in characteristics of
hydrophobicity and the surface charge of
bacteria vary between species and strains
(Hogt et al. 1985). Hydrophobic interac-
tions influence the adherence of hydropho-
bic bacteria more than they influence
hydrophilic ones; in regard to hydrophobic
interactions, similar bacteria prefer a simi-
lar surface, which in practice means that
hydrophobic bacteria adhere more eagerly
to a hydrophobic surface (Satou et al. 1988).
As to adherence of hydrophilic bacteria,
electrostatic interactions seem to be more
important (Satou et al. 1988). The bacterial
surface charge in an aqueous medium is
negative, but this negative charge is higher
for hydrophilic bacteria (Hogt et al. 1985). 
Surface chemical composition plays a
major role in bacterial adhesion to medical
devices such as sutures (Chu and Williams
1984). Metal surfaces are hydrophilic;
polymers such as polyethylene and Teflon
are hydrophobic (An and Friedman 1998).
Basically, surface hydrophobicity leads to
increased bacterial adhesion, but some bac-
teria have unique adhesion affinities for
certain materials (Timmerman et al. 1991).
For example, Staphylococcus epidermidis
adheres more easily to polymers and
Staphylococcus aureus more easily to metal
surfaces (An and Friedman 1998).  The
overall surface area and configuration also
influence bacterial adhesion. Rough sur-
faces and braided, porous, or grid-like sur-
face configurations have a greater surface
area and provide more depressions for safe
colonization; this also influences biofilm
formation (Chu and Williams 1984, Quiry-
nen et al. 1993, Verheyen et al. 1993). The
surface charge also has some influence on
bacterial adherence (Emery et al. 2003)
although this is less important than sur-
face hydrophobicity (An and Friedman
1998). 
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Biofilm formation
An accumulated mass of micro-organisms
and their extracellular slime material of
proteins, polysaccharides, or both on a
solid surface is called biofilm (An and
Friedman 1998). Biofilm forms on any
kind of material when bacteria adhere to
surfaces in aqueous environments and
begin to excrete a slimy, glue-like substance
that can anchor them and provide protec-
tion from phagosytosis and other host
defense mechanisms (Barth et al. 1989,
Costerton and Stewart 2001). The bacteria
in biofilm display a different phenotype
than do free-living bacteria (Costerton et
al. 1995, Erdos et al. 2003), and their meta-
bolic and division rate is greatly reduced,
leading to resistance against antibiotics and
against standard bacterial cultures (Fitzger-
ald and Williams 1975). A biofilm can be
formed by a single bacterial species, but
more often biofilms consist of many
species of bacteria, debris, and corrosion
products (Costerton et al. 1999). Antibiot-
ic treatment is able to affect the peripheral
bacteria in biofilm, but deeper organisms
are resistant to virtually all treatment and
act as a center for regrowth and periodic
bacterial bursts that lead to new bouts of
acute infections (Stewart and Costerton
2001, Ehrlich et al. 2002). Furthermore,
susceptibility to antimicrobial agents can be
diminished by the active exchange of resist-
ance plasmids that occurs in biofilms (Don-
lan 2001). For these reasons, recurrent
implant-derived infections are best cured
with removal of the implanted device, but
this leads to increases in time and costs
for treatment, not to mention discomfort
for the patient (Gristina 1987, Donlan
2001). Although it has been known since
the 1970s that most of the bacteria in
nature live in biofilm colonies, knowledge
of infectious diseases is mainly based on
studies made with free-floating, planctonic
bacteria (Manning 2003). 
During recent years, more evidence of
the presence of biofilm in AOM and OME
has been gathered (Post 2001, Fergie et al.
2004). This biofilm formation occurs in
chronically infected in-dwelling medical
devices such as voice prostheses (Everaert et
al. 1999, Free et al. 2001) and TTs
(Biedlingmaier et al. 1998, Post 2001). The
resistance of these biofilm bacteria to antibi-
otic treatment can explain the failure of
antibiotic treatment in chronically draining
TT and the fact that otorrhea in a tube ear is
usually cured by removal of the tube. Fur-
thermore, evidence exists for the presence
of bacterial biofilm formation in human
cholesteatoma (Chole and Faddis 2002). 
Protein and platelet adhesion 
and blood clotting
Protein adhesion on a biomaterial surface is
based on physical and chemical interac-
tions similar to those of bacterial adher-
ence (An and Friedman 1997). Protein
adhesion is important because when bio-
material is exposed to blood or extracellular
fluid, almost immediately a surface layer
of proteins form (Chang 1973, Brynda et
al. 2000) that can affect the subsequent
adsorption of micro-organisms and
platelets on the surface (Vaudaux et al.
1984, Herrmann et al. 1988). One of the
typical proteins able to adhere to an implant
surface and bind bacteria is fibronectin
(Mosher and Proctor 1980, Kuusela et al.
1985), a cell-glue protein distributed by all
body fluids (Vaheri and Salonen 1988). On
the other hand, some adhered proteins
such as albumin change bioimplants’ sur-
face properties so that adhesion of other
molecules and initiation of coagulation
response is inhibited (Hyde et al. 1999). In
intravenous devices, the biomaterial can be
designed to favor the albumin adhesion
essential for their hemocompatibility (Man-
tero et al. 2001). 
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An especially problematic form of
unwanted adhesion on synthetic materials
exposed to circulating blood (Chang 1973) is
platelet adhesion and the subsequent sur-
face-induced thrombosis. In intravenous
implants such as catheters, the prevention
of such adhesion is crucial for implant
function. Furthermore, platelet adhesion
can mediate bacterial adhesion on a sur-
face, and this can finally lead to septic
embolisms (Wang et al. 1993).
2.3.4 PREVENTION OF 
UNDESIRABLE ADHESION 
Because in practice all implanted biomate-
rial devices are naturally exposed to body
fluids such as blood, saliva, pus, or extra-
cellular fluid and their proteins and other
components that can facilitate bacterial
adhesion and biofilm formation, the bio-
materials are sometimes pretreated with
molecules possessing antiadherent or
antimicrobial properties (Zdanowski et al.
1993). Surface coatings can influence bac-
terial adhesion by altering implant-surface
properties such as charge or hydrophobici-
ty (Brokke et al. 1991). An antiadherent
coating is characterized by its strong adher-
ence to surfaces and its ability to prevent
adhesion of cells and other biological sub-
stances simultaneously without its having
any actual antimicrobial properties (Hyde et
al. 1999). The absorbed protein layer
reduces surface hydrophobicity and raises
net negative charge and thus reduces adhe-
sion of both hydrophobic and hydrophilic
bacteria that are both negatively charged
(Hogt et al. 1985). This is the theoretical
basis for albumin coating. Changes in sur-
face charge and hydrophobicity can be
achieved also by ion-coating of the surface
(Sioshansi 1994). Biedlingmaier et al. have
shown that biofilm formation may be
reduced in implants coated with bombard-
ing ions, although they have made no quan-
titative comparisons between this and other
methods (Biedlingmaier et al. 1998, Saidi et
al. 1999). 
An antimicrobial coating can diminish
bacterial adherence on an implant surface.
Silver oxide (AgO) antimicrobial coating
has been effective in urinary tract catheters
and TTs (Lundeberg 1986, Chole and
Hubbell 1995). 
Albumin coating
A typical example of antiadherent coating is
albumin. Albumin is the main plasma pro-
tein and has a high net negative charge and
strong surface-binding activity (Tullis
1977a, b). Albumin produces a smooth
monolayer coating (Ton et al. 1979) that
inhibits bacterial and other adhesion on the
surface by increasing the surface negative
charge that promotes electrostatic repul-
sion between bacteria and surface, and by
reducing the surface hydrophobicity that
diminishes adherence of the more adhe-
sive hydrophobic bacteria (Hogt et al. 1985,
Reynolds and Wong 1983, Brokke et al.
1991). Surface coating with albumin also
prevents adhesive contact by blocking active
binding sites on the surface and by binding
and inactivating part of the normally con-
tact-activated plasma proteins (Eberhart et
al. 1987). Albumin coating can be achieved
by suspending the material preoperatively
in an albumin solution (An et al. 1996) or,
as in some intravenously implanted devices,
by coating the surface with albumin-bind-
ing molecules such as carbon alkyl chains
that rapidly and selectively bind albumin
from the bloodstream (Chang 1969, Eber-
hart et al. 1987). 
Characteristic for albumin is its strong
surface adherence by hydrophobic interac-
tion (Tullis 1977a). Inhibition of bacterial
adherence on an albumin-coated titanium
surface has been shown to remain higher
than 85% throughout a 20-day study of tita-
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nium plates implanted in rabbits (An et al.
1997). A cross-linking agent, usually car-
bodi-imide, is sometimes used with the
albumin coating in arterial grafts or ortho-
pedic implants (Ben Slimane et al. 1988 a
and 1988 b). Chang has shown that albu-
min, even without a cross-linking agent,
attaches firmly to the surfaces of a hemop-
erfusion system and produces a very thin
and smooth layer, not displaced by fibrino-
gen in the circulating blood, even with a
high blood flow-rate of 300 ml/min (Chang
1974). 
The effect of a serum albumin coating in
preventing platelet aggregation and blood-
clot formation on a biomaterial surface was
first reported in 1967 by Packham and col-
leagues and introduced in more detail 2
years later (Chang  1969, Packham et al.
1969). Since these first in vivo tests, coating
of implants with human serum albumin
(HSA) has been investigated actively in sev-
eral medical fields both to repel unwanted
adhesion on artificial implant materials and
to prevent bleeding through porous vascular
prostheses at implantation (Chang  1974,
Remuzzi and Boccardo 1993, al-Khaffaf and
Charlesworth 1996, Brynda et al. 2000).
The antithrombogenic properties of albu-
min coating have been tested both in extra-
corporeal hemoperfusion devices and in arti-
ficial heart valves (Chang 1974, Hyde et al.
1999). Albumin coating also prevents fib-
rinogen and IgG adsorption on artificial sur-
faces in extracorporeal hemodialyzer mem-
branes and pacemaker leads, and prevents
bacterial as well as leukocyte adhesion on
titanium implants and vascular prostheses
made of polytetrafluoroethylene and Dacron
(Lubin et al. 1986, Kottke-Marchant et al.
1989, Zdanowski et al. 1993, McDowell et
al. 1995, An et al. 1996). The inhibitory
effect of albumin coating on bacterial adher-
ence and of postoperative infections on
orthopedic titanium implants has been test-
ed both in vitro and in vivo (An et al. 1996
and 1997). 
Commercially available HSA is nor-
mally concentrated from donor blood.
Because albumin is an exceptionally stabile
protein, it is routinely processed with 60 °C
heating for several hours (Tullis 1977 a).
As a result of this pasteurization, all known
viral pathogens are eradicated (Erstad
1996). Moreover, blood donors in Finland
are tested to assure that they are negative
for HIV and hepatitis viruses. Albumin has
excellent viral safety records despite over
60 years of its abundant intravenous use as
a plasma expander (Erstad 1996), which
has in recent years amounted to over 5 mil-
lion doses annually worldwide (Vincent et
al. 2003). The rarely occurring hazards con-
nected with use of albumin are based on
anaphylactic reactions in high-dose intra-
venous infusions (Vincent et al. 2003). 
When biocompatibility of albumin as
an implant coating was tested, no signifi-
cant difference appeared in total circulat-
ing T cells or in the IL-2 receptor-positive
cell subset between rats with albumin-coat-
ed and uncoated vascular grafts implanted
intraperitoneally. This was true even when
the grafts were coated with xenogenic
human serum albumin, which represents a
more severe immunological challenge
(Marois et al. 1996). HSA has served as a
surface coating in arterial grafts for over a
decade. In a 5-year follow-up study of albu-
min-coated vascular prostheses, no albu-
min-derived viral infections or other disad-
vantages occurred in a group of 200
patients (al-Khaffaf and Charlesworth
1996). 
26
27
28
Because undesirable adherence of bacteria and proteins of effusion and blood on TT sur-
faces can cause tube occlusions and recurrent infections that often lead to tube removal,
this study was designed to gain experience as to the effect of an antiadherent albumin coat-
ing in reducing TT sequelae. 
Specific questions to be answered: 
1. What is the effect of albumin coating in preventing adherence of fibronectin, the
most abundant “cell glue” in exudates, on the surface of five standard TTs, each made
of different material?
2. Do the antiadherent properties of albumin-coated TTs survive during 8-month storage
of the tube in different environments?
3. Can albumin coating prevent bacterial adherence on a titanium surface?
4. What is the effect of albumin coating on tube sequelae in a patient with an albumin-
coated TT in one ear and an uncoated, but otherwise identical tube in the other ear in
a prospective, double-blind clinical trial?
29
3
AIMS OF THE STUDY
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4.1 TYMPANOSTOMY TUBES (I, II, IV)
All TTs used in the experiments were com-
mercially available tubes manufactured by
Medtronic Xomed, Inc., in Jacksonville, FL,
USA. The tube models, materials, and the
Roman numeral of the study in which they
were used appear in Table I. Two (I) or
three (II) HSA-coated tubes were compared
to an equal number of uncoated tubes in
the in vitro experiments. In the clinical trial
(IV) each child received an HSA-coated tita-
nium tube in one ear and an uncoated, oth-
erwise identical titanium tube in the other.
4.2 TITANIUM PLATES (III)
Bacterial adhesion on HSA-coated surfaces
was tested with titanium plates because the
complex shape of TTs makes quantifica-
tion of the adhered bacteria unreliable.
Commercially pure titanium plates of size 
5 x 5 x 1.2 mm were polished with a silicone
carbide polishing paper up to P 1200 so
they all had identical surface structure
under light microscopy prior to exposure
to bacteria. Three HSA-coated and uncoat-
ed plates were used to test the adherence of
each bacteria.
4.3 HUMAN SERUM ALBUMIN (HSA)
In the first in vitro experiment it was evi-
dent that an extremely small amount of
serum albumin is sufficient to coat fully a
TT surface. HSA produced by the Finnish
Red Cross Blood Transfusion Service was
the choice for the clinical trial because it is
tested for medical use. Coating methods
with the cross-linking introduced earlier by
other authors were also tested. Altogether,
the four methods to obtain the albumin
coating were: 
1. Albumin coating with 0.01% HSA
resulted when 200 µl purified HSA
(Sigma, St. Louis, MO, USA) in a con-
centration of 0.1 mg/ml was used to
immobilize the albumin on the TTs sur-
faces at room temperature overnight (I,
II).
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MATERIALS AND METHODS
Table I. TTs in Studies I, II, and IV.
Tube model Material Study
Soileau Tytan Titanium I, II, IV
Donaldson Type Silicone Silicone I, II
Donaldson Type Fluoroplastic Teflon I
Donaldson Type C-flex Thermoplastic elastomer I
Donaldson Type Activent Silicone with AgO coating I
2. Albumin coating with 1% HSA resulted
when 250 µl purified HSA (Human
Albumin SPR 40 mg/ml, Finnish Red
Cross Blood Transfusion Service,
Helsinki, Finland) at a concentration of
40 mg/ml, diluted with 750 µl phos-
phate-buffered saline (PBS), was used to
immobilize the albumin on a titanium
plate (III) or titanium tube (IV) surface
at room temperature overnight.
3. Albumin coating with 2% HSA, sup-
plemented with cross-linked carbodi-
imide, resulted from soaking silicone
tubes in a mixture of 1.0 ml purified
4% HSA (Sigma) and 1.0 ml of 0.2% M
carbodi-imide (Sigma) for 10 minutes to
immobilize the albumin with its cross-
linkage on the TT surface (An et al.
1996), (II).
4. Albumin coating with 4% HSA resulted
when 200 µl purified HSA (Human
Albumin SPR 40 mg/ml, Finnish Red
Cross Blood Transfusion Service) at a
concentration of 40 mg/ml was used
to immobilize the albumin on the TT
surface at room temperature overnight
(II).
4.4 FIBRONECTIN (I, II)
Fibronectin, a typical protein in serum and
exudates known as one of the most adher-
ent glycoproteins, is also called “cell glue.”
It is widely distributed in all body fluids as
well as in connective tissue matrices in sol-
uble and insoluble form (Vaheri and Salo-
nen 1988). Fibronectin served as a model to
represent glue proteins in exudates of the
ear in studies I and II. Fibronectin, 200 µg
suspended in 200 µl of Tris-buffer con-
taining 1 mM EDTA, was radiolabeled with
0.5 mCi of  125I in Iodogen-tubes according
to the Iodo-Gen method (Pierce Chemical
Co., Milwaukee, WI, USA). The free iodine
was removed from the radiolabeled
fibronectin on a G-25 gel chromatography
column (PD-10, Pharmacia, Täby, Sweden).
To detect fibronectin adhesion on the TT
surfaces, a duplicate (I) or triplicate (II) of
five different tube types (Table I), either
coated with HSA or uncoated, was incu-
bated with 800 ng of 125I-labeled fibronectin
overnight. The bound radioactivity was
counted after several washes with a gamma
counter (Wallac, Turku, Finland). 
4.5 TUBE STORAGE (II)
To test the durability of the antiadherent
properties of the HSA coating on the TT
surface, silicone tubes (Medtronic Xomed)
were stored for 2 weeks, 4 weeks, 3 months,
and 8 months. To mimic the conditions
that TTs and tube coatings must normally
endure, the trial was carried out in three
different environments: a dry +4 °C, a dry
+37 °C, and a humid +37 °C. After storage,
binding of radiolabeled fibronectin on
HSA-coated and uncoated tubes was tested.
Because in warm, humid conditions bac-
terial contamination of test devices hap-
pens almost inevitably if the test is contin-
ued for months, the study was halted at 4
weeks in the humid +37 °C environment.
The experiment was organized so that the
fibronectin adhesion test was made for all
the tube groups at the same time. The tubes
stored for 8 months were put first in the
storage chambers 8 months before the
actual adhesion test, and the tubes to be
stored for one month were put into stor-
age last, 7 months later, one month before
the adhesion test.
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4.6 SCANNING ELECTRON
MICROSCOPY (SEM)
A scanning electron microscope Zeiss
DSM 962 (Oberkochen, Germany) was
used to visualize TT surface changes after
coating of the tubes with HSA. Titanium
and silicone tubes (Medtronic Xomed) test-
ed were prepared for the SEM with a plat-
inum coating.  Magnifications were x50
and x500 (II). 
A pair of TTs that extruded from each
ear of one patient after 9 months in the
clinical trial (IV), after preparation with gold
coating, were viewed with JEOL JSM 6335F
(JEOL USA, Inc. Peabody, MA, USA) SEM.
The magnifications were x100 and x500. 
4.7 BACTERIA (III) 
Adherence of typical pathogens causing
severe contamination problems in TTs was
tested in an in vitro experiment. Staphylo-
coccus aureus and Pseudomonas aeruginosa
were chosen to represent these bacteria
because they are able to form biofilm and
are over-represented in chronic and recur-
rent infections of ears with TTs (Brook et al.
1998, Mandel et al. 1994). The bacteria
were commercial strains of Staphylococcus
aureus and Pseudomonas aeruginosa. S.
aureus (ATCC 25923) was cultured in Todd-
Hewitt broth at +37 °C overnight under con-
tinuous orbital shaking; P. aeruginosa
(ATCC 27853) was cultured at +37 °C over-
night on chocolate plates made in Myller-
Hinton II broth (19 g/l) and trypticase soy
agar (29 g/l) (Becton, Dickinson & Co.
Cockeysville, MD, USA). Both bacteria were
suspended in PBS to give the final concen-
tration of 1—5 x 108 colony-forming units
/ml (CFU/ml), based on optical density at
600 nm (S. aureus) or as confirmed by plate
counts (P. aeruginosa).
Three HSA-coated and three uncoated
titanium plates were exposed to the bacteria
in a suspension at room temperature for
90 minutes. Plates were rinsed with PBS
and aqua, dried at room temperature, and
thereafter dyed with acridine orange prior
to quantification of the bacteria under flu-
orescence microscopy.
4.8 FLUORECENCE MICROSCOPY
AND QUANTIFICATION OF 
BACTERIA (III)
The titanium plates, viewed with the fluo-
rescence microscope Zeiss Axioplan 2 (Carl
Zeiss Vision GmbH, München-Hallberg-
moos, Germany) at x63 and 10 fields sized
428 x 339 µm (1300 x 1030 pixels), were
photographed with a Zeiss AxioCam HRc
(Carl Zeiss). The picture-processing pro-
gram ImageJ (National Institute of Health,
Washington, DC, USA) was used to calcu-
late the amount of surface area coated with
fluorescent bacteria.
4.9 PATIENTS AND PROSPECTIVE
STUDY DESIGN (IV)
Altogether 179 children undergoing bilat-
eral tympanostomy due to bilateral OME
or RAOM were enrolled in the prospective,
double-blind clinical study with a 9-month
follow-up. Inclusion criteria were: MEE
without symptoms of AOM persisting at
least 3 months (OME) or three or more
AOM attacks during the preceding 6
months (RAOM). Patients were excluded
from the trial if they had unilateral otologic
problems. Into each child in the study was
inserted one uncoated titanium tube and
one HSA-coated but otherwise identical
tube. These were randomized so that the
HSA-coated tube was inserted into either
the left or right ear. Because HSA coating is
visible only under high magnification in
SEM (II), the operation and follow-up were
truly double blind.
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Of the 179 patients, 146 were operated
on at the Department of Otorhinolaryngol-
ogy at Helsinki University Central Hospital
(HUCH), and the other 33 were operated on
at Jorvi Hospital in Espoo. Nine patients
(5%) were lost to follow-up, so statistical
analysis was based on data from 170
patients; of these, 108 (64%) were male
and 62 (36%) female. Ages ranged from 6
months to 15 years, median age 3.8 years.
The number of primary tube insertions was
106 (62%) and that of secondary tube inser-
tions 64 (38%). All patients had satisfied
the inclusion criteria: RAOM for 63 (37%),
and OME for 107 (63%) patients.
In the surgical procedure, the ear canal
was cleaned, an anteroinferior quadrant
incision was made in the tympanic mem-
brane, and any middle ear effusion was
aspirated before the tube was inserted
through the tympanic membrane. The
patency of the TT was secured with suction
if needed. Any excessive bleeding requir-
ing suction or treatment with adrenalin was
recorded. In the same operation, ade-
noidectomy was performed on 94 (55%) of
the patients.
In postoperative follow-up, the patients
were examined by an ear, nose, and throat
(ENT) specialist at 1, 3, 6, and 9 months
after the procedure. Follow-up of the 146
patients undergoing surgery at HUCH was
done by the author at HUCH. The patients
having surgery at Jorvi Hospital were fol-
lowed up by the author and other ENT spe-
cialists at the Leppävaara Health Care Cen-
ter in Espoo. At each visit, number of AOM
attacks and drainage time of the possible
otorrhea in each ear, results of bacterial cul-
tures, and number of upper respiratory
infections since the previous examination
were documented.  Pneumatic otoscopy
and tympanometric evaluation with the GSI
38 Auto Tymp (Grason-Stadler, Inc. Mil-
ford, NH, USA) were performed to evaluate
TT and middle ear status. In selected cases,
otomicroscopy or audiometry was done if
needed. Ears with otorrhea were treated
with suction and saline irrigation repeated
every other day if needed, bacterial cultures
were made, and the patients were treated
with conventional oral and antibiotic thera-
py and eardrops. Acute otologic problems
between the follow-up examinations were
treated at health care centers or private out-
patient clinics, according to the Finnish rec-
ommendations of good clinical practice.
A tympanometric test was used to eval-
uate both the middle ear ventilation
through the TT and middle ear status after
the tube had extruded or occluded. The GSI
38 Auto Tymp tympanometer has an ear
canal volume (ECV) function that can
assess a possible open air route into the
middle ear cavity through the tympanic
membrane. ECV is over 1 cm3 in cases with
tympanic membrane perforation or open
TT because both ear canal volume and vol-
ume of the middle ear and mastoid cavity
are counted (Shanks et al. 1992). In this
respect, in tympanostomized ears three dif-
ferent types of results in tympanometry can
appear:
1. Type B (flat) curve and ECV over 1 cm3
as a result of open TT or perforation in
the tympanic membrane, allowing air
passage to the middle ear.
2. Type A or C curve: Healthy middle ear
with occluded or extruded tube. 
3. Type B curve and ECV under 1 cm3:
OME in ear with occluded or extruded
tube.
If the tube inner flange is seen above the
tympanic membrane, and tympanometry
shows results of type 2 or 3, tube extrusion
is diagnosed. Even in cases where the tube
is tilted, giving no straight view into the
tube lumen, one can distinguish whether
the tube is open, blocked, or extruded with
these specifications. 
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4.10 ETHICAL ASPECTS
In the prospective study (IV), parents of all
the patients enrolled signed an informed
consent prior to each study procedure. The
study protocol was approved by the Ethics
Committee of Helsinki University Central
Hospital. 
4.11 STATISTICAL METHODS
The statistical analyses were performed
with the SPSS 9.0 (SPSS, Inc., Chicago,
IL, USA) program for all the in vitro studies
and in analyzing results of the in vivo study.
The criterion for statistical significance was
α=0.05 for all experiments.
In the first in vitro experiment (I), bind-
ing of  125I -labeled fibronectin was detected
on two uncoated and HSA-coated TTs of
each tube type. Mean values of the bound
fibronectin were compared to find the pos-
sible binding inhibition achieved by HSA
coating. In the study on the durability of
HSA coating (II), the mean values of
fibronectin adherence were tested in tripli-
cate, but otherwise identically to the first
in vitro experiment. Furthermore, in that
study, a combined calculation was per-
formed on fibronectin adhesion in all stor-
age environments, comparing groups by
the Kruskall-Wallis test; data were present-
ed with standard error of mean. 
Study of bacterial adherence (III) was
also done in triplicate. Mean values of plate
surface areas covered with adhered bacteria
were compared.
In the prospective study (IV), prolonged
tube ventilation time, as a result of dimin-
ished number of early tube occlusions, was
chosen as the principal endpoint. The min-
imum sample size was calculated with the
NCSS 2000 statistical program (NCSS Sta-
tistical Software, Kaysville, UT, USA). For
this calculation, incidence of tube occlu-
sions was determined to be 7% for conven-
tional tubes (Kay et al. 2001) and 1% for
HSA-coated tubes as predicted by the
results of the first in vitro experiment (I).
The minimum sample size needed was 170
when the criterion for statistical signifi-
cance was α=0.05 and desired statistical
power 1-β=0.9. For statistical analysis of
the results, it was assumed that tube seque-
lae such as tube occlusion or extrusion
occurred midway between the two exami-
nation dates, since the patients were exam-
ined at intervals from 1 to 3 months. For the
dichotomous outcome variables such as
tube occlusions, the standard χ2 test was
used. Continuous variables were statisti-
cally evaluated with the student t-test.
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5.1 IN VITRO EXPERIMENTS
5.1.1 PROTEIN ADHESION STUDIES 
(I, II)
In the first two experiments, the binding-
inhibition test was used to study the anti-
adherent properties of HSA coating. Bind-
ing inhibition is the reduction in binding of
any model protein or other molecule, in
this case fibronectin, on a surface, a reduc-
tion achieved by the surface treatment. 
Experiment I showed that the amount
of HSA needed to coat a TT surface fully is
extremely small, 1 µg or even less per tube.
It also showed that the amount of
fibronectin actually needed to saturate the
surface of one TT, coated or uncoated, was
much less than the 800 ng routinely used
in these experiments, and only 2% to 12%
of the fibronectin was attached to the tube
surfaces.
For all tube materials independent of
storage time or environment, HSA coating
reduced the binding of fibronectin. Varia-
tion per tube in fibronectin binding
between different tube models was small.
In uncoated tubes, binding ranged from
101 ng (12.6% of the total 800 ng of
fibronectin available) for the C-flex tubes
to 73 ng (9.1%) for the titanium tube. A
larger difference, from 4.5 ng to 101 ng,
however, was evident when HSA-coated
and uncoated tubes where compared (I, II).
When the tubes were not stored, the bind-
ing inhibition achieved with HSA coating
ranged from 59% to 85%, depending on
tube material, (Table II). The highest bind-
ing inhibition occurred in titanium and sil-
icone-AgO tubes: 84.6% and 84.2%. 
Durability of binding inhibition was
tested 1, 3, and 8 months in three different
environments that resemble by humidity
and temperature the conditions in which
the tubes are stored and used. An inhibito-
ry effect of HSA coating on fibronectin
adhesion was evident in all environments
even after an 8-month storage, although
some drop in binding inhibition occurred
in warm and humid conditions (Fig. 1).
Whether this drop was due to decay of HSA
on the surface remains unclear. 
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RESULTS AND COMMENTS
Table II. Binding inhibition of fibronectin achieved with 
human serum albumin (HSA) -coating in tympanostomy tubes.
C-flex 69.0%
Fluoroplastic 59.2%
Silicone 68.8%
Silicone-AgO 84.2%
Titanium 84.6%
In a dry, cold environment, the drop in
binding inhibition was small. After an 8-
month storage at a dry +4 °C, binding inhi-
bition of fibronectin was 74%. The decline
in binding inhibition was more marked
when the tubes were stored at a higher tem-
perature. Binding inhibition was 41% after
a 3-month storage and 27% after an 8-
month storage at a dry +37 °C. At a humid
+37 °C, binding inhibition after 4 weeks
was 63%. The overall binding of fibronectin
on HSA-coated tympanostomy tubes was
significantly smaller in all storage environ-
ment groups
Of the four HSA coating methods,
when the durability of albumin coating with
0.01% HSA and 4% HSA was compared
with that of albumin coating with 2% HSA,
supplemented with cross-linked carbodi-
imide, fibronectin binding was higher in
the latter, which thus had no advantage over
coatings of pure albumin, even in the 8-
month trial.
These results show that any TT surface
when coated with HSA achieves a strong
inhibition of fibronectin binding. The dif-
ference in fibronectin adhesion between
tube models was in part due to the differ-
ence in their total surface area and to their
original tube surface characteristics, espe-
cially roughness. For example, the differ-
ence in fibronectin binding to two uncoated
tubes identical in model: silicone (75ng)
and silicone-AgO (96ng), can be explained
by the fact that the AgO coating increases
roughness and thus the surface area of the
silicone tube increases. 
5.1.2 SCANNING ELECTRON
MICROSCOPY 
In SEM, both silicone and titanium tubes
showed some larger grooves, probably due
to molding. At small magnification, only a
slight difference was evident between coat-
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Fig 1. Combined results of fibronectin binding on tympanostomy tubes stored
under dry conditions at +4°C and +37°C.
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Fig. 2. Uncoated (a) and HSA-coated (b) titanium tube surfaces (magnification x500).
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Fig. 3. Extruded titanium tubes. 
a) Uncoated, b) HSA-coated tubes (magnification x100 and x500).
ed and uncoated tubes. At higher magnifi-
cations, differences between the albumin-
coated and uncoated tubes could be seen
more clearly (Fig. 2). The uncoated surface
appeared generally rougher, and some
deeper pores and scars could be seen in
detail. Albumin coating produces a smooth
film that covers the uneven surface of the
tubes. The tubes could be seen as densely
coated with albumin. Roughness had
enlarged the overall surface area of the
uncoated tube and thus provided more area
for adhesion of foreign materials.
In SEM pictures of extruded titanium
tubes, a thick crust on the surface of the
uncoated tube and a smooth film-like albu-
min coating without crust formation on the
HSA-coated tube are visible (Fig. 3). 
The tubes ventilated normally for 9
months and thereafter were extruded and
removed from the ear canal. Preoperatively,
this patient had bilateral OME and at sur-
gery mucoid effusion in the ear into which
the HSA-coated tube was inserted; the other
ear with the uncoated tube had been dry.
During follow-up, the patient had no ear
infections, and both tubes functioned nor-
mally (unpublished data). 
SEM pictures of the extruded tubes
show that crust formation was inhibited on
the albumin-coated titanium surface
(unpublished data).  
5.1.3 BACTERIAL ADHERENCE STUDY
(III)
Calculation of bacterial adherence to tita-
nium surfaces was by the picture process-
ing program ImageJ (NIH, USA).
For Staphylococcus aureus, 0% to 14.6%
of the photographed titanium surface was
covered with bacteria (Fig. 4). HSA coating
inhibited the adherence of S. aureus to the
titanium surface significantly in both the
108 and the 5 x 108 CFU/ml bacterial con-
centrations tested. For the lower (108
CFU/ml) bacterial concentration, on aver-
age 1.6% of the uncoated and 0.22% of the
HSA-coated titanium surface was covered
with bacteria, which meant an 82% adher-
ence inhibition. For the higher (5 x 108
CFU/ml) bacterial concentration, on aver-
age 6.5% of the uncoated and 0.25% of the
HSA-coated titanium surface was covered
with bacteria, so the adherence was inhib-
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Fig 4. Uncoated (a) and HSA-coated (b) titanium plates exposed to 
Staphylococcus aureus dyed with acridine orange (magnification x64).
ited 95%. In each case, the difference was
significant (P < 0.05).
With Pseudomonas aeruginosa, 0.3% to
58.8% of the photographed titanium sur-
face was covered with bacteria (Fig.5). HSA
coating reduced adherence of P. aeruginosa
to the titanium surface in both (1 x 108 and
5 x 108 CFU/ml) bacterial concentrations
tested. At the lower concentration, on aver-
age 5.0% of the uncoated and 3.3% of the
HSA-coated titanium was covered with bac-
teria, which meant a 29% decrease in
adherence achieved with HSA coating. In
the higher concentration, in which on aver-
age 25.4% of the uncoated and 16.8% of
the HSA–coated surface was covered with
bacteria, adherence was inhibited 37%. For
the higher concentration, this difference
was significant (P < 0.05). For the lower,
108 CFU/ml concentration, the difference
was not significant (P=0.09).
Excellent visualization of both bacteria
was achieved with acridine orange fluores-
cent staining. The plate surface area cov-
ered with fluorescent bacteria was count-
ed with a picture-processing program.
This study showed that adherence of
both S. aureus and P. aeruginosa to a titani-
um surface can be inhibited significantly
by HSA coating. This inhibition was more
marked with S. aureus but was also signifi-
cant at the higher concentration tested with
P. aeruginosa. The difference in binding
inhibition between bacterial species, as also
demonstrated here, is possibly due to the
fact that the adherence of a bacterium on a
surface is dependent not only on the char-
acteristics of the substratum, such as charge
and hydrophobicity, but also on the charac-
teristics of the bacterial surface, which vary
among bacterial species and strains (An
and Friedman 1998).
5.2 PROSPECTIVE CLINICAL STUDY
(IV)
5.2.1 PERIOPERATIVE FINDINGS
Physical appearance of the middle ear con-
tents in this procedure, in the ears with
HSA-coated and uncoated tubes, was found
to be similar. The surgeon reported exces-
sive perioperative bleeding in 24 (14%)
patients, in 15 ears with HSA-coated and
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Fig 5. Uncoated (a) and HSA-coated (b) titanium plates exposed to 
Pseudomonas aeruginosa dyed with acridine orange (magnification x 64).
in 14 ears with uncoated tubes. Bleeding
was always reported when suction or other
procedures were needed to stop it.
5.2.2 POSTOPERATIVE FINDINGS
Overall ventilation time was longer with
HSA-coated tubes (7.1 months) than with
uncoated tubes (6.8 months), but with no
significant difference. In the 24 patients
with excessive bleeding during surgery, a
significant prolongation in ventilation time
(paired sample t-test, P < 0.05) occurred in
HSA-coated tubes (7.6 months versus 5.8
months).
Otorrhea occurred in 68 (40%) of the
patients and in 95 (28%) of the tubes dur-
ing the 9-month follow-up. No significant
difference between HSA-coated and uncoat-
ed tubes appeared, although the number
of HSA-coated tubes involving otorrhea: 42
(25%), versus 53 (31%) ears, was smaller.
An equal numbers of ears, 5 (3%), with
recurrent acute otorrhea, meaning 3 or
more episodes during the follow-up, had
HSA-coated or uncoated tubes. The num-
bers of chronic otorrhea cases, meaning
drainage for more than 3 weeks, were also
almost equal in number among HSA-coat-
ed and uncoated tubes, 6 (3.5%) and 5 (3%).
Tube occlusion was found at the 3-
month follow-up visit significantly less
often in HSA-coated tubes than in uncoat-
ed tubes, 12 (7%) and 24 (14%) (χ2 test, P <
0.05). At the 9-month follow-up visit, this
difference, although again present, was not
statistically significant: 59 (34%) to 70
(41%). Most (76%) of the tubes collected at
least some dry crust or other impurity dur-
ing follow-up. In this respect, no difference
appeared between coated and uncoated
tubes.
Tube extrusion occurred at the 3-month
follow-up visit in 7 (4%) of ears with both
HSA-coated and uncoated tubes. At the 9-
month follow-up visit, 45 (26%) HSA-coat-
ed and 39 (23%) uncoated tubes had
extruded.
After tube extrusion, tympanosclerotic
plaque appeared in a total of 23 (7%) ears,
in an almost equal number of ears for
extruded HSA-coated and uncoated tubes,
11 (6%) and 12 (7%) ears. Granulation tis-
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Table III. Sequelae of TT treatment.
Ear with Ear with 
HSA-coated tube uncoated tube
Total ears 170 170
Average tube ventilation time (months) 7.1 6.8
At least one otorrhea episode 42 53
Recurrent otorrhea 5 5
Chronic otorrhea 5 6
Tube occlusion within 3 months 12 24 χ2 test P < 0.05
Tube occlusion within  9 months 59 70
Early tube extrusion within 3 months 7 7
Tympanosclerosis 11 12
Granulation 13 17
Chronic perforation 0 1
sue appeared around the tube in a total of
30 (9%) of the ears, in 13 (8%) ears with an
HSA-coated tube and 17 (10%) with an
uncoated tube (n.s.). Chronic perforation
of the tympanic membrane occurred in one
(0.3%) ear that had had an uncoated tube.
No cholesteatoma occurred in these
patients. Sequelae found in the trial are list-
ed in Table III.
As predicted by the results of the in vitro
experiments, a reduction in number of
tubes with occlusion and in cases of otor-
rhea occurred with use of HSA coating.
Tube occlusion was diagnosed when a tube
had crust in its lumen, the inner tube
flange was behind the tympanic mem-
brane, and ECV was under 1 cm3 in tympa-
nometry. The results show that the number
of occlusions in HSA-coated tubes at the
3-month follow-up visit was half the num-
ber of occlusions in uncoated tubes. Fur-
thermore, among the 24 patients with peri-
operative bleeding, ventilation time with
the HSA-coated tube was 31% longer. The
number of occluded TTs seemed to rise
during follow-up. After one month it was 17
(5%), at the 3-month visit 36 (11%), at the 6-
month visit 75 (22%), and finally at the 9-
month visit 129 (38%). Because the healing
process of the tympanic membrane in
some cases seems to repair the tympanic
membrane perforation under the tube
while the tube is still in the tympanic mem-
brane—leading to ECV under 1 cm3 in tym-
panometry, and thus satisfying the diag-
nostic criteria for an occluded tube—the
number of tube occlusions may have been
overestimated after the first 6 months of
follow-up. The difference in tube occlusion
between the coated and uncoated tubes was
more obvious in the first months of follow-
up, and thereafter the difference became
smaller, which may be due to gradual decay
of the coating or to the fact that eventually
almost all tubes are covered with crust
which may make their HSA coating inef-
fective.
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Acute otitis media is an extremely common
disease among children, with many chil-
dren suffering from recurrent attacks. Oti-
tis media with effusion is a typical outcome
of AOM and one of the most common rea-
sons for hearing loss among children. A
great amount of energy is focused on the
diagnosis, treatment, and follow-up of pedi-
atric ear diseases all of which place an
enormous financial burden on families and
the community. Tympanostomy has
become the treatment of choice in any
OME unresponsive to nonsurgical treat-
ment that has lasted for 3 months, and it is
widely used also in treating recurrent AOM.
In recent decades, tympanostomy has
become one of the most common surgical
operations under general anesthesia among
children in many countries, and several
million TTs are manufactured yearly world-
wide. Recently, bacterial antibiotic resist-
ance has made the role of surgical proce-
dures in treating RAOM and OME even
more important (Bluestone 1998).  
All otologists are familiar with the frus-
trating problems involving functioning of
TTs: occlusion of the tube and otorrhea.
This thesis directed its focus toward the
most critical reasons for sequelae in the tym-
panostomized ear: adhesion of cell glue pro-
tein and bacteria on the TT surface. One
surface mechanical solution for this prob-
lem, albumin coating, was tested. The proj-
ect was originally initiated to create a coating
method to achieve antiadherent properties
in otological devices. The first in vitro exper-
iment on an HSA coating found it to cause
excellent inhibition of fibronectin binding
onto TTs (I). This experiment showed the
potential benefits of the method and was
preliminary to in vitro and in vivo experi-
ments. The principal endpoint chosen for
the whole project was prevention of unwant-
ed adhesion on the tube surface, leading to
prolonged tube ventilation time. Investiga-
tions of TTs emphasizing tube surface char-
acteristics exist to only a very limited extent.
In this respect, two surface treatment meth-
ods were introduced earlier on: Silver-oxide
coating and surface treatment with bom-
barded ions. Chole and Hubbell (1995)
showed that otorrhea occurs less often in
TTs coated with AgO. The Biedlingmaier
group showed that an ion-treated TT sur-
face can repel biofilm formation (Biedling-
maier et al. 1998, Saidi et al. 1999), but the
incidence of TT occlusion in these experi-
ments remains unreported.
HSA possesses excellent antiadherent
properties that are useful in hemodialysis
devices to reduce platelet adherence on arti-
ficial surfaces. HSA-precoated arterial grafts
in clinical use can prevent blood leakage
through the porous graft immediately after
an operation. They have also shown prom-
ising results in reduction of bacterial and
other undesirable adhesion on arterial grafts
and orthopedic titanium implants. Although
HSA comes from donor blood, it is safe
from blood-derived viral pathogens because,
unlike the other blood products, it can be
pasteurized at +60 °C for over 10 hours
(Tullis 1977a). HSA has an excellent safety
record despite its abundant use as a plasma
expander for the last 60 years. In recent
years, worldwide annual intravenous use of
HSA has been over 5 million doses. Fur-
thermore, the biocompatibility of HSA coat-
ing on arterial grafts has been tested in a 5-
year follow up study (Marois et al. 1996).
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GENERAL DISCUSSION 
6.1 IN VITRO EXPERIMENTS (I, II, III)
6.1.1 STUDIES ON FIBRONECTIN
ADHESION 
It is known that HSA coating reduces
adherence of proteins such as fibrinogen
on biomaterial surfaces (Kottke-Marchant et
al. 1989), and fibronectin was chosen for
testing because it excellently represents the
adhesion properties of body fluids (Vaheri
and Salonen 1988). Moreover, studies prior
to the first in vitro experiment showed that
the crust adhering to the TT surface con-
sists mostly of proteins such as fibronectin
(unpublished data). The fibronectin binding
test adopted from earlier studies (Cannas et
al. 1990) allowed testing of this new treat-
ment to prevent protein adhesion and crust
formation on TT surfaces. Fibronectin
adherence diminished significantly (59%-
85%) with HSA coating in all tube materials
tested, even compared with Teflon, well
known for its antiadherent properties also
in TTs (Karlan et al. 1980). The number of
tube types tested was limited to five.
Although samples per group numbered
only two, which could lead to bias, the dif-
ference was significant for all tube types.
That gold tubes were unavailable for testing
is frustrating, especially when in Finland
use of gold or gold-plated TTs has recently
increased.
Because to be useful the favorable prop-
erties of any surface treatment should sur-
vive long-term storage and wear in the ear
in many environments, a durability trial
tested binding inhibition of fibronectin by
HSA after storage for 1, 3, and 8 months.
Although some increase occurred in all
tubes in fibronectin binding during this
storage time, endurance of binding inhibi-
tion was high when the tubes were stored at
+4°C. Some decline in binding inhibition
occurred at +37 °C. Because TTs have little
contact with surrounding tissue, less wear
of the surface coating is expected than in
totally implanted biomaterials such as
orthopedic implants, although some HSA
coating may gradually decay off the tube
surface.
Three coating methods comprised the
one from the first in vitro experiment, a
0.01% HSA coating, versus an HSA coating
(2%) with a carbodi-imide cross-link intro-
duced earlier by An et al. (1996) to show
whether cross-linking enhances durability
(Ben Slimane et al. 1988a), versus the new
coating method with HSA manufactured
by the Finnish Red Cross Blood Transfu-
sion Service to be used in the clinical trial.
No major difference appeared between the
three methods. The HSA coating with car-
bodi-imide cross-linking showed no advan-
tage over the use of pure albumin coating
in an 8-month trial; cross-linking of albu-
min coating has not been previously com-
pared to coatings without cross-linking. An
and colleagues (1996) found similar dura-
bility in a shorter trial of bovine serum albu-
min-coated titanium cylinders kept for 20
days at +37 °C in PBS with intermittent agi-
tation: Inhibition of albumin coating on
Staphylococcus epidermidis adherence
remained greater than 85%. Durability of
other surface treatments on TTs has not
been reported. Because the present experi-
ment included only silicone TTs, these
results are not comparable to those with
other materials. The number of tubes in
each study group was raised here to three,
to avoid any bias due to small sample num-
ber.
6.1.2 SCANNING ELECTRON
MICROSCOPY
Differences between uncoated and HSA-
coated tubes in SEM pictures were obvious
(Fig. 2). In the extruded tube (Fig. 3), is vis-
ible a thick layer of dry crust on the uncoat-
ed tube surface, although this patient did
not suffer from otorrhea during follow-up
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and had perioperative effusion only in the
ear with the HSA-coated tube. No further
conclusions can be drawn from pictures of
only one pair of TTs, although they sup-
port the theory of Karlan et al. (1980), who
has shown in SEM pictures that the sur-
face character of a TT has an influence on
bacterial adhesion and that subsequent
otorrhea occurs less often in ears with
smoother Teflon tubes. Earlier, similar find-
ings on the character of crust formation in
extruded TTs are from Reid et al (1988)
with light microscopy and Saidi et al.
(1999) with SEM. 
6.1.3 STUDIES ON BACTERIAL 
ADHERENCE 
Few if any papers quantitatively compare
bacterial adherence on different TT sur-
faces, although some studies describe
biofilm formation and bacterial adherence
on tube surfaces (Karlan et al. 1980,
Biedlingmaier et al. 1998). The reason for
so few studies may be the same as in this
thesis: A double-flanged grommet TT is
extremely complex in form for reliable
detection of number of bacteria adhered to
its surface. For testing bacterial adherence
on an HSA-coated titanium surface, titani-
um plates instead of the tubes were thus
chosen. Earlier tests of S. aureus, and S. epi-
dermidis adhesion on bovine serum albu-
min-coated orthopedic titanium implants
in vitro found that adherence can be inhib-
ited by 90% with albumin coating (McDow-
ell et al. 1995). Furthermore, to test the in
vivo effect of albumin coating in orthopedic
titanium implants (An et al. 1997), titanium
implants, after being incubated in S. epi-
dermidis, were inserted subcutaneously into
rabbits. Postoperative wound infection
occurred in 62% of the rabbits receiving
uncoated titanium implants and in only
27% with bovine serum albumin-coated
titanium implants. 
In the present in vitro experiment on
bacterial adherence, the two most common
bacteria in chronic infections of tympanos-
tomized ears were used, Staphylococcus
aureus and Pseudomonas aeruginosa. Adher-
ence of S. aureus was inhibited from 82% to
95% depending on concentration of the
bacterial suspension. Adherence of P. aerug-
inosa was inhibited from 29% to 37%. The
results with S. aureus were identical with
results of McDowell et al. (1995). The dif-
ference in adherence on an HSA-coated
surface between these two bacterial species
can be due to the fact that their adherence is
dependent on both substratum, and bacte-
rial surface characteristics (An and Fried-
man 1998). 
An in vitro experiment like this has its
limitations. Exposure of one bacterial
species to an implant surface without
biofilm formation would be a very unusual
situation in vivo. The in vivo lifecycle of an
implanted device is a different and far more
complex process than the situation in vitro;
the former includes the simultaneous influ-
ence of several bacteria, as well as bio-
chemical and mechanical stress, not to
mention the effects of the host defense
mechanism. These in vitro results, howev-
er, strongly indicate that biofilm formation
can also be reduced on pretreated titanium
surfaces.
6.2 IN VIVO STUDY (IV)
The principle of comparing two TT in the
contralateral ears of each patient is widely
used (Handler et al. 1986 and 1988, Chole
and Hubbell 1995). In half the clinical, con-
trolled TT studies, the tubes are compared
between contralateral ears and in the other
half compared in a parallel group of
patients (Kay et al. 2001). In the present
prospective trial, inclusion criteria were
based on recommendations (Bluestone and
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Klein 1995) of practitioning otologists and
also from many clinical trials (Gordts et al.
1993). 
Although albumin coating of
implantable materials has been investigated
for several decades, few if any prospective,
randomized clinical trials have appeared.
A 5-year follow-up of 200 patients with
HSA-coated arterial grafts has shown good
results, although with no comparison of
other methods included (Al-Khaffaf and
Charlesworth 1996). Several retrospective
and prospective trials compare two or more
TTs. Because an obvious difference usually
exists between the TTs compared, all these
trials except one (Chole and Hubbell 1995),
were not double-blind. Another basic prob-
lem in these past experiments is the fact
that conclusions focus mostly on one fea-
ture of the tube, usually its material, such as
gold or titanium (Handler et al. 1986 and
1988), although the tubes compared differ
in several features such as lumen size, tube
form, or length. Sometimes other features
than the one focused upon are not even
reported (Gordts et al. 1993). This fact may
have led to unreliable assumptions stem-
ming from such reports.
In the present prospective study (IV),
perioperative findings were similar to those
of many follow-up trials (Chole and Hubbel
1995, Cunningham and Harley 1991),
although differences may exist between
inclusion criteria—difference seldom pre-
sented in the older reports. Furthermore,
the present findings are in accordance with
findings of the clinical trials excellently
combined in a meta-analysis based on 134
articles (Kay et al. 2001) (Table IV). 
The principal endpoint of the clinical
study was prolonged ventilation time result-
ing from a lower number of tube occlu-
sions; occlusions, according to Kay et al.
(2001), are the most frequent adverse side-
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Table IV. Sequelae of tympanostomy tube treatment.
Kinnari et al.  Kay et al. meta-analysis
(2004) (2001)
340 ears 13 760 ears
Sequelae Incidence Incidence Range
% % %
At least one otorrhea episode 28 17 3.0–74.0
Recurrent otorrhea 3.0 2.1 1.2–3.4
Chronic otorrhea 3.2 3.3 1.9–7.7
Tube occlusion 37 6.9 0–37.3
Early tube extrusion within 3 months 3.9 4.0 1.1–8.3
Tympanosclerosis 7 31.7 7.2–64.3
Granulation 9 4.2 0–12.0
Chronic perforation 0.3 2.2 0–12.3
Cholesteatoma 0 0.8 0–6.5
Tube displacement into middle ear 0 0.5 0–1.3
effect of an indwelling tube. Studies on the
outcome of TTs have seldom reported the
ventilation time of the tubes, but used the
term “tube retention time” or reported the
tube extrusion time, which is, by defini-
tion, the time at which the entire medial
flange of the tube is seen to be out of con-
tact with the tympanic membrane (Moore
1990). This issue is understandable,
because of the difficulty in defining
whether a tube is occluded or extruded.
This may, however, lead to over-apprecia-
tion of long-lasting TTs, despite the fact
that often the long-lasting tubes are occlud-
ed during the last months of their stay in
the tympanic membrane, when they, being
foreign objects, promote only sequelae.
It is obvious that a certain interval exists
between the end of successful ventilation
time and tube extrusion. In this prospective
study, this interval varied between 0 and
8.5 months (unpublished data). A tube
extrusion was defined as occurring when
the tube inner flange was visible over the
tympanic membrane, and tympanometry
resulted in an ECV under 1 cm3. It is possi-
ble that this definition leads to overestima-
tion of the number of tube occlusions,
which in this material was 37%, because
some tympanic membrane healing can
happen under a TT, allowing normal move-
ment by the tympanic membrane even
before the tube has actually extruded. 
A high number of occlusions in titani-
um TTs (25%) was also found by Handler
et al. (1988). This, together with the results
of this thesis, shows that overall occlusion
rate may be higher with titanium tubes or
that occlusion and partial extrusion are par-
ticularly difficult to differentiate for titani-
um tubes, due to the very thin flanges that
may remain inside the tympanic mem-
brane during the healing process. Based on
the results of this thesis, it is obvious that
the large variation in number of tube occlu-
sions in previous studies (0%—36%) is at
least partly related to these problems in
defining tube occlusion. The difference in
number of early tube occlusions between
HSA-coated and uncoated tubes in this
prospective study is at least real, not the
result of a difference in diagnosing extru-
sion and tube occlusion between coated and
uncoated tubes. The reason is that at the 3-
month visit, the number of tube extrusions
(7) was the same for both tube types, but
the number of tube occlusions (12) in HSA-
coated tubes was half that  for uncoated
tubes (24). Moreover, the percentage of
occluded tubes at the 3-month visit, 7% for
HSA-coated and 14% for uncoated tubes, is
similar to the percentage reported earlier
for Teflon tubes (10.5%) (Jamal 1995).
Because the major benefits of the HSA
coating were predicted to be evident during
the first months of follow-up, the random-
ized follow-up was ended at the 9-month
visit.  During that time, only 25% of the
tubes extruded, so some of the postopera-
tive findings, such as average ventilation
time and changes in tympanic membrane,
are underestimated and some, such as need
for re-tympanostomy, cannot be presented
at all.
These results show that significantly
fewer early tube occlusions occur in HSA-
coated tubes, and—especially in cases with
excessive blood contact with the tube during
surgery—tube occlusions are fewer, lead-
ing to prolonged ventilation time with
HSA-coated tubes. No adverse effects of
albumin coating were shown in this or ear-
lier studies. These results constitute one
step forward in the search for the optimal
tympanostomy tube.
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1. A TT coated with HSA can resist adhesion of fibronectin, the most abundant adhesive
glycoprotein in exudates. 
2. HSA will produce a smooth coating attached firmly to the TT surface. Resistance to
fibronectin adhesion achieved with HSA coating is durable in an 8-month durability
test.
3. HSA-coated titanium plates are resistant in vitro to adherence of Staphylococcus aureus
and Pseudomonas aeruginosa, bacteria typical of chronic implant-derived infections
such as chronic otorrhea in a tympanostomized ear.
4. In a clinical trial, HSA-coated TTs showed half the number of early tube occlusions as
did uncoated TTs. Furthermore, among patients with excessive perioperative bleeding,
ventilation time for HSA-coated tubes was 31% longer than for uncoated tubes. 
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CONCLUSIONS
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